ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

Results from the phase 2 DESTINY-CRC01  trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU®     (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment. These results were presented today at the 2020 American Society of Clinical Read more about ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial[…]

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved a clinically meaningful tumor Read more about ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial[…]

Innovation and Resiliency Drive Dell Technologies’ First Quarter Fiscal 2021 Financial Results

Dell Technologies effectively navigates COVID-19 environment with innovative products, broad capabilities, flexible supply chain and resilient global workforce First quarter revenue of $21.9 billion Operating income up 28% to $702 million, non-GAAP operating income of $2.2 billion Client Solutions Group revenue up 2% to $11.1 billion; VMware revenue up 12% Dell Technologies (NYSE: DELL) announces financial results for its fiscal 2021 first quarter. First quarter Read more about Innovation and Resiliency Drive Dell Technologies’ First Quarter Fiscal 2021 Financial Results[…]

Early skin cancer detection should not be neglected!

May is Skin Cancer Awareness Month, and there is a reason for that. Due to the often insidious development over time, the threat of skin cancer is often underestimated. Due to the Corona pandemic, the importance of regular skin checks is sometimes completely neglected – although especially in the case of malignant melanoma, early detection Read more about Early skin cancer detection should not be neglected![…]

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 pm ET. Immunic’s management and invited key opinion leaders, specializing in multiple sclerosis and inflammatory Read more about Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020[…]

Plugging instead of screwing: Safe and fast filling of oxygen cylinders with WEH Connectors

In cases of particularly severe courses of Covid-19, mechanical ventilation with oxygen is often the only way to save a patient’s life. Even in less severe cases, oxygen supply supports the patients in breathing. With the increasing spread of the corona virus, the need for medical oxygen has therefore risen sharply. In practice, this means Read more about Plugging instead of screwing: Safe and fast filling of oxygen cylinders with WEH Connectors[…]

A new drug to treat COVID-19: TR-C 19 at human testing phase

VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.   At VSY Biotechnology GmbH, we are very excited to announce that a new drug, named TR-C 19, has been developed to treat COVID-19 by the VSY Biotechnology R&D team. Read more about A new drug to treat COVID-19: TR-C 19 at human testing phase[…]

Eurochannel now available on Swisscom TV in Switzerland

Eurochannel, the world’s leading European cinema channel, expands its presence in Switzerland with a launch on Swisscom TV. Eurochannel is now available to Swisscom TV subscribers. For the first time, Eurochannel is offered in a German language version on Top Deutsch+ package. Eurochannel is also available in a French language version on Top Français+ package. Read more about Eurochannel now available on Swisscom TV in Switzerland[…]

EcoVadis: Silver status for Gerresheimer in sustainability audit

With 58 out of a maximum possible 100 points, Gerresheimer currently belongs to the top 6 percent of companies evaluated by EcoVadis in the comparative sector of pharmaceutical suppliers and medical technology. Numerous international pharma and cosmetics customers regularly review Gerresheimer with regard to sustainable corporate management. Many carry out this through recognized external CSR Read more about EcoVadis: Silver status for Gerresheimer in sustainability audit[…]

VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual

. – Results from first nine patients include three objective responses – Two of these patients are progression-free >6 months – VXM01 in combination with avelumab was safe and produced specific immune responses – Results accepted for an oral presentation at conference VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today Read more about VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual[…]